The Clinical Accelerator team actively monitors the rapidly evolving cancer immunotherapy landscape, and we work directly with companies to source innovative agents to be evaluated by our scientific network in our combination clinical trials. As such, the Clinical Accelerator team has established a broad network of biotech and industry partners to enable access to 38 different clinical-stage agents that could be used to support various combination immunotherapy trials. The table below provides the list of the targets organized by different mechanisms of action.
Targets of 38 Clinical-Stage Agents
Cancer Vaccine Targets
Oncolytic Virus Targets
Bispecific Antibody Targets
- PI3K delta